An overview of the
current data from PsoProtectMe
Current Data
We are committed to sharing data and are delighted to provide open access to summary information from PsoProtectMe. These data are preliminary and include a limited number of participants, so should not be used to inform clinical decision making.
Participants per country (≥10 participants):
| Country | Participants | Country | Participants |
|---|---|---|---|
| Argentina | 60 | Panama | 11 |
| Australia | 27 | Peru | 14 |
| Canada | 41 | Philippines | 52 |
| Chile | 107 | Poland | 28 |
| Denmark | 50 | Portugal | 202 |
| Hong Kong | 18 | Singapore | 12 |
| India | 16 | Spain | 65 |
| Ireland | 33 | Sweden | 34 |
| Japan | 87 | United Kingdom | 1715 |
| Netherlands | 12 | United States | 171 |
| Norway | 14 | Other (<10) | 122 |
Summary data from PsoProtectMe’s first 2000 participants.
Average age: 47 years (range 3-91)
Average BMI: 26 kg/m2
Type of psoriasis: 1678 plaque psoriasis, 431 guttate psoriasis, 109 pustular psoriasis, 41 erythrodema
Gender:
Smoking status:
Coexisting psoriatic arthritis:
Type of psoriasis treatment:
Psoriasis severity change during the pandemic:
Have you been diagnosed with or thought you had COVID-19?
Did you go to hospital A&E due to your COVID-19?
Did you stay in hospital due to your COVID-19?
Has your COVID-19 infection got better?